Taken together, our experiments nicely confirmed our hypothesis that the p53 status of cancer cells could serve as a predictive marker, which can be used to select patients who will profit from a combinatorial Plk1 and PKCβ inhibition therapy, especially to treat the p53-deficient cancers. The gene discussed is PRKCB; the disease is cancer.